MARCH 17, 2008 - Apieron, Inc. announced that the Insight eNO system has received clearance to market by the U.S. Food and Drug Administration. The Insight eNO system measures exhaled nitric oxide (eNO) which is a well established indicator of airway inflammation and asthma control. The Insight system is a highly accurate device, expressly designed for the physician’s office. It is non-invasive, safe, easy to use, and provides results in less than a minute. Apieron’s unique biosensor detects trace amounts of nitric oxide molecules in a single human breath utilizing a proprietary technology. Current methods and techniques used to diagnose, monitor and treat asthma are costly, time-consuming and cumbersome. Physician office measurement of eNO is a much awaited breakthrough in medical technology that provides physicians with a reliable tool to measure their patients’ respiratory inflammation better than ever before. Measurement of eNO has also been shown to optimize medication therapy and improve compliance among patients with asthma... Apieron's Press Release -
